Literature DB >> 30373916

US drug prices should be tied to foreign prices to tackle "global freeloading," says Trump.

Owen Dyer1.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 30373916     DOI： 10.1136/bmj.k4542

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.

Authors:  Bin Wu; Shun Lu
Journal:  Transl Lung Cancer Res       Date:  2020-10

2.  Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

Authors:  Yitian Lang; Deshi Dong; Bin Wu
Journal:  Clin Drug Investig       Date:  2020-10-23       Impact factor: 2.859

3.  Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.

Authors:  Bin Wu; Fei Ma
Journal:  Ther Adv Med Oncol       Date:  2020-05-05       Impact factor: 8.168

4.  Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Authors:  SiNi Li; JianHe Li; LiuBao Peng; YaMin Li; XiaoMin Wan
Journal:  Front Oncol       Date:  2021-05-28       Impact factor: 6.244

5.  Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer.

Authors:  Xuezhi Hao; Aizong Shen; Bin Wu
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

6.  Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.

Authors:  Dan Su; Bin Wu; Lizheng Shi
Journal:  JAMA Netw Open       Date:  2021-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.